Cinacalcet failure raises trial conduct issues By Sally Robertson.

Nevertheless, unanticipated baseline features and high crossover rates resulted in reduced capacity to properly test the drug’s effects, say investigators Glen Chertow and co-workers. The true insights from this research are for scientific trialists and regulators, say Vlado Perkovic and Bruce Neal in an accompanying editorial. We need to change the way we study the consequences of new medications and integrate these changes into regulatory procedures, guideline development, and clinical practice. Related StoriesArtemisinin and the fight against malaria: an interview with Dr. An interview with Professor Lesley JonesThe Evaluation of Cinacalcet Hydrochloride Therapy to lessen Cardiovascular Occasions trial showed a nonsignificant 7 percent decrease in risk for death or major CV occasions among individuals with end-stage renal disease who received cinacalcet compared with those who received placebo.In 2012, CSL Behring renewed its item donation contract with WFH, for the time 2013 through 2015. Since 2012, CSL Behring offers donated close to 7.7 million IUs of its bleeding disorders therapies to treat people who have hemophilia or von Willebrand disease in developing countries.

China’s SFDA finds certain batches of Jiangsu Yanshen’s human make use of rabies vaccine substandard Simcere Pharmaceutical Group , a leading pharmaceutical company focusing on the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that China’s State Food and Drug Administration issued a statement on its investigation into the human use rabies vaccine manufactured simply by Jiangsu Yanshen Biological Technology Stock Co., Ltd.